Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
| Active as of 2024-04-27 |
Resource Citation "179613" Version "1" Updated "2023-11-26 18:47:26+0000"
url: https://fevir.net/resources/Citation/179613
identifier: FEvIR Object Identifier/179613, https://pubmed.ncbi.nlm.nih.gov/27308831
version: 1.0.0-ballot
title: 27308831 Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.
status: active
date: 2024-04-27 20:42:39+0000
publisher: HL7 International / Clinical Decision Support
contact: HL7 International / Clinical Decision Support: http://www.hl7.org/Special/committees/dss
description: This Citation Resource is referenced in an example for the EBMonFHIR Implementation Guide.
| Code | Value[x] |
| FEvIR Platform Use (Details: http://hl7.org/fhir/citation-classification-type code fevir-platform-use = 'FEvIR Platform Use', stated as 'FEvIR Platform Use') | Medline Base (Citation Artifact Classifier#medline-base) |
jurisdiction: World (m49.htm#001)
copyright: https://creativecommons.org/licenses/by-nc-sa/4.0/
approvalDate: 2017-07-26
lastReviewDate: 2022-03-17
author: Computable Publishing®: MEDLINE-to-FEvIR Converter:
classification
type: Citation Source (Citation Classification Type#citation-source)
classifier: MEDLINE ()
classification
type: MEDLINE Citation Owner (Citation Classification Type#medline-owner)
classifier: National Library of Medicine, Index Section (elements_descriptions.html#owner_value#NLM)
currentState: Medline Citation Status of Medline (Citation Status Type#medline-medline), PubMed PublicationStatus of epublish (Citation Status Type#pubmed-publication-status-epublish)
statusDate
activity: PubMed Pubstatus of Received (Citation Status Type#pubmed-pubstatus-received)
period: ?? --> 2016-04-01
statusDate
activity: PubMed Pubstatus of Accepted (Citation Status Type#pubmed-pubstatus-accepted)
period: ?? --> 2016-06-02
statusDate
activity: PubMed Pubstatus of Entrez (Citation Status Type#pubmed-pubstatus-entrez)
period: ?? --> 2016-06-17 06:00:00+0000
statusDate
activity: PubMed Pubstatus of Pubmed (Citation Status Type#pubmed-pubstatus-pubmed)
period: ?? --> 2016-06-17 06:00:00+0000
statusDate
activity: PubMed Pubstatus of Medline (Citation Status Type#pubmed-pubstatus-medline)
period: ?? --> 2017-07-27 06:00:00+0000
citedArtifact
identifier:
https://pubmed.ncbi.nlm.nih.gov/27308831,https://www.ncbi.nlm.nih.gov/pmc//PMC4911003,https://doi.org/10.1371/journal.pone.0157660, pii/PONE-D-16-10077Titles
Type Language Text Primary title (Title Type#primary) English (Tags for the Identification of Languages#en) Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis. Abstracts
Text **OBJECTIVE:** Prostate cancer is the most common nonskin cancer and second most common cause of cancer mortality in older men in the United States (USA) and Western Europe. Androgen-deprivation therapy alone (ADT) remains the first line of treatment in most cases, for metastatic disease. We performed a systematic review and meta-analysis of all randomized controlled trials (RCT) that compared the efficacy and adverse events profile of a chemohormonal therapy (ADT ± docetaxel) for metastatic hormone-naive prostate cancer (mHNPC). **METHODS:** Several databases were searched, including MEDLINE, EMBASE, LILACS, and CENTRAL. The primary endpoint was overall survival. Data extracted from the studies were combined by using the hazard ratio (HR) or risk ratio (RR) with their corresponding 95% confidence intervals (95% CI). **RESULTS:** The final analysis included 3 trials comprising 2,264 patients (mHNPC). Patients who received the chemohormonal therapy had a longer clinical progression-free survival interval (HR = 0.64; 95% CI: 0.55 to 0.75; p<0.00001), and no heterogeneity (Chi2 = 0.64; df = 1 [p = 0.42]; I2 = 0%). The biochemical progression-free survival (bPFS) also was higher in patients treated with ADT plus docetaxel (HR = 0.63; 95% CI: 0.57 to 0.69; p<0.00001), also with no heterogeneity noted (Chi2 = 0.48; df = 2 [p = 0.79]; I2 = 0%). Finally, the combination of ADT with docetaxel showed a superior overall survival (OS) compared with ADT alone (HR = 0.73; 95% CI: 0.64 to 0.84; p<0.0001), with moderate heterogeneity (Chi2 = 3.84; df = 2 [p = 0.15]; I2 = 48%). A random-effects model analysis was performed, and the results remained favorable to the use of ADT plus docetaxel (HR = 0.73; 95% CI: 0.60 to 0.89; p = 0.002). In the final combined analysis of the high-volume disease patients, the use of the combination therapy also favored an increased overall survival (HR = 0.67; 95% CI: 0.54 to 0.83; p = 0.0003). Regarding adverse events and severe toxicity (grade ≥3), the group receiving the combined therapy had higher rates of neutropenia, febrile neutropenia and fatigue. **CONCLUSION:** The combination of ADT with docetaxel improved the clinical progression-free survival, bPFS and OS of patients with mHNPC. A superior OS was seen especially for patients with metastatic and high-volume disease. This contemporary combination therapy may now be offered as a first-line treatment for selected patients. relatesTo
type: cites
citation: http://clinicaltrials.gov/ct2/show/NCT00514540.
relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Beltran H, Beer TM, Carducci MA, de Bono J, Gleave M, Hussain M, et al. New therapies for castration-resistant prostate cancer: efficacy and safety. Eur Urol. 2011;60(2):279–90. Epub 2011/05/20. doi: S0302-2838(11)00477-5 [pii] 10.1016/j.eururo.2011.04.038 .
Documents
Url https://pubmed.ncbi.nlm.nih.gov/21592649/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/21592649relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Botrel TE, Clark O, Pompeo AC, Bretas FF, Sadi MV, Ferreira U, et al. Immunotherapy with Sipuleucel-T (APC8015) in patients with metastatic castration-refractory prostate cancer (mCRPC): a systematic review and meta-analysis. International braz j urol: official journal of the Brazilian Society of Urology. 2012;38(6):717–27. Epub 2013/01/11. .
Documents
Url https://pubmed.ncbi.nlm.nih.gov/23302410/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/23302410relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Loblaw DA, Virgo KS, Nam R, Somerfield MR, Ben-Josef E, Mendelson DS, et al. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol. 2007;25(12):1596–605. Epub 2007/04/04. doi: JCO.2006.10.1949 [pii] 10.1200/JCO.2006.10.1949 .
Documents
Url https://pubmed.ncbi.nlm.nih.gov/17404365/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/17404365relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. European urology. 2014;65(2):467–79. Epub 2013/12/11. 10.1016/j.eururo.2013.11.002 .
Documents
Url https://pubmed.ncbi.nlm.nih.gov/24321502/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/24321502relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Parker C, Gillessen S, Heidenreich A, Horwich A. Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26 Suppl 5:v69–77. Epub 2015/07/25. 10.1093/annonc/mdv222 .
Documents
Url https://pubmed.ncbi.nlm.nih.gov/26205393/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/26205393relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Noguchi M, Noda S, Yoshida M, Ueda S, Shiraishi T, Itoh K. Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist. Int J Urol. 2004;11(2):103–9. Epub 2004/01/07. .
Documents
Url https://pubmed.ncbi.nlm.nih.gov/14706014/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/14706014relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr., Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. The New England journal of medicine. 2004;351(15):1513–20. Epub 2004/10/08. 10.1056/NEJMoa041318 .
Documents
Url https://pubmed.ncbi.nlm.nih.gov/15470214/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/15470214relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. The New England journal of medicine. 2004;351(15):1502–12. Epub 2004/10/08. 10.1056/NEJMoa040720 .
Documents
Url https://pubmed.ncbi.nlm.nih.gov/15470213/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/15470213relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Fizazi K, Jenkins C, Tannock IF. Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra. Ann Oncol. 2015;26(8):1660–7. Epub 2015/05/24. 10.1093/annonc/mdv245
Documents
Url https://pubmed.ncbi.nlm.nih.gov/26002607/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/26002607relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. The Lancet Oncology. 2013;14(2):149–58. Epub 2013/01/12. 10.1016/s1470-2045(12)70560-0 .
Documents
Url https://pubmed.ncbi.nlm.nih.gov/23306100/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/23306100relatesTo
type: cites
citation: Gravis G, Boher JM, Joly F, et al. Androgen deprivation therapy plus docetaxel versus ADT alone for hormone-naive metastatic prostate cancer: Long-term analysis of the GETUG-AFU 15 phase III trial. 2015 Genitourinary Cancers Symposium Abstract 140 Presented February 26, 2015.
relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Gravis G, Boher JM, Joly F, Soulie M, Albiges L, Priou F, et al. Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial. European urology. 2015. Epub 2015/11/28. 10.1016/j.eururo.2015.11.005 .
Documents
Url https://pubmed.ncbi.nlm.nih.gov/26610858/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/26610858relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. The New England journal of medicine. 2015;373(8):737–46. Epub 2015/08/06. 10.1056/NEJMoa1503747
Documents
Url https://pubmed.ncbi.nlm.nih.gov/26244877/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/26244877relatesTo
type: cites
citation: Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Impact on overall survival (OS) with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial. J Clin Oncol 32:5s, 2014. (suppl; abstr LBA2).
relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ. 1994;309(6964):1286–91. Epub 1994/11/12. .
Documents
Url https://pubmed.ncbi.nlm.nih.gov/7718048/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/7718048relatesTo
type: cites
citation: Clarke M, Oxman AD, (Editors). Cochrane Reviewers Handbook 4.1.1 [updated December 2000] In: The Cochrane Library, Issue 4, 2000. Oxford, Update Software.2000.
relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Castro AA, Clark OA, Atallah AN. Optimal search strategy for clinical trials in the Latin American and Caribbean Health Science Literature database (LILACS database): update. Sao Paulo Med J. 1999;117(3):138–9. Epub 1999/10/08. doi: S1516-3180(99)11700311 [pii]. .
Documents
Url https://pubmed.ncbi.nlm.nih.gov/10511734/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/10511734relatesTo
type: cites
citation: Egger M, Smith GD, Altman D. Systematic Reviews in Health Care. London: BMJ Books; 2001.
relatesTo
type: cites
citation: Review Manager (RevMan) [Computer program]. Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17(24):2815–34. Epub 1999/01/28. [pii]. .
Documents
Url https://pubmed.ncbi.nlm.nih.gov/9921604/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/9921604relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60. Epub 2003/09/06. 10.1136/bmj.327.7414.557 327/7414/557 [pii].
Documents
Url https://pubmed.ncbi.nlm.nih.gov/12958120/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/12958120relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Yang K, Wang YJ, Chen XR, Chen HN. Effectiveness and safety of bevacizumab for unresectable non-small-cell lung cancer: a meta-analysis. Clin Drug Investig. 2010;30(4):229–41. Epub 2010/03/17. doi: 2 [pii] 10.2165/11532260-000000000-00000 .
Documents
Url https://pubmed.ncbi.nlm.nih.gov/20225906/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/20225906relatesTo
type: cites
citation: Deeks JJ, Higgins JP, Altman DG. Analysing and presenting results In: Higgins JP, G S editor. Cochrane Handbook for Systematic Reviews of In- terventions (ed 426 [updated September 2006]). Chichester, United Kingdom: John Wiley & Sons Ltd; 2006.
relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88. Epub 1986/09/01. doi: 0197-2456(86)90046-2 [pii]. .
Documents
Url https://pubmed.ncbi.nlm.nih.gov/3802833/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/3802833relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34. Epub 1997/10/06.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/9310563/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/9310563relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: McQuay HJ, Moore RA. Using numerical results from systematic reviews in clinical practice. Ann Intern Med. 1997;126(9):712–20. Epub 1997/05/01. .
Documents
Url https://pubmed.ncbi.nlm.nih.gov/9139558/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/9139558relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Smeeth L, Haines A, Ebrahim S. Numbers needed to treat derived from meta-analyses—sometimes informative, usually misleading. BMJ. 1999;318(7197):1548–51. Epub 1999/06/04.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/10356018/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/10356018relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Altman DG, Deeks JJ. Meta-analysis, Simpson's paradox, and the number needed to treat. BMC Med Res Methodol. 2002;2:3 Epub 2002/02/28.
Documents
Url https://pubmed.ncbi.nlm.nih.gov/11860606/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/11860606relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151(4):W65–94. Epub 2009/07/23. doi: 0000605-200908180-00136 [pii].
Documents
Url https://pubmed.ncbi.nlm.nih.gov/19622512/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/19622512relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Fizazi K, Faivre L, Lesaunier F, Delva R, Gravis G, Rolland F, et al. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. The Lancet Oncology. 2015;16(7):787–94. Epub 2015/06/02. 10.1016/s1470-2045(15)00011-x .
Documents
Url https://pubmed.ncbi.nlm.nih.gov/26028518/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/26028518relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Nakabayashi M, Xie W, Buckle G, Bubley G, Ernstoff MS, Walsh W, et al. Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer. Urology. 2013;81(3):611–6. Epub 2013/03/05. 10.1016/j.urology.2012.12.025 .
Documents
Url https://pubmed.ncbi.nlm.nih.gov/23452809/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/23452809relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Thalgott M, Horn T, Heck MM, Maurer T, Eiber M, Retz M, et al. Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer. Journal of hematology & oncology. 2014;7:20 Epub 2014/03/07. 10.1186/1756-8722-7-20
Documents
Url https://pubmed.ncbi.nlm.nih.gov/24598155/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/24598155relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Mottet N, Peneau M, Mazeron JJ, Molinie V, Richaud P. Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial. European urology. 2012;62(2):213–9. Epub 2012/04/17. 10.1016/j.eururo.2012.03.053 .
Documents
Url https://pubmed.ncbi.nlm.nih.gov/22502942/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/22502942relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Warde P, Mason M, Ding K, Kirkbride P, Brundage M, Cowan R, et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet (London, England). 2011;378(9809):2104–11. Epub 2011/11/08. 10.1016/s0140-6736(11)61095-7
Documents
Url https://pubmed.ncbi.nlm.nih.gov/22056152/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/22056152relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet (London, England). 2009;373(9660):301–8. Epub 2008/12/19. 10.1016/s0140-6736(08)61815-2 .
Documents
Url https://pubmed.ncbi.nlm.nih.gov/19091394/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/19091394relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Amato R, Stepankiw M, Gonzales P. A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer. Cancer chemotherapy and pharmacology. 2013;71(6):1629–34. Epub 2013/04/23. 10.1007/s00280-013-2163-4 .
Documents
Url https://pubmed.ncbi.nlm.nih.gov/23604530/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/23604530relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Rajan P, Frew JA, Wilson JM, Azzabi AS, McMenemin RM, Stockley J, et al. Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer. Urol Oncol. 2015;33(8):337.e1–6. Epub 2015/06/21. 10.1016/j.urolonc.2015.05.012 .
Documents
Url https://pubmed.ncbi.nlm.nih.gov/26092557/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/26092557relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: James ND, Spears MR, Clarke NW, Dearnaley DP, De Bono JS, Gale J, et al. Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). European urology. 2015;67(6):1028–38. Epub 2014/10/11. 10.1016/j.eururo.2014.09.032 .
Documents
Url https://pubmed.ncbi.nlm.nih.gov/25301760/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/25301760relatesTo
type: cites
citation: James ND, Sydes MR, Mason M, et al. Docetaxel and/or zoledronic acid for hormone-naïve prostate cancer: First overall survival results from STAMPEDE (NCT00268476). J Clin Oncol 33, 2015. (suppl; abstr 5001).
relatesTo
type: cites
citation: Patrick-Miller LJ, Chen YH, Carducci MA, Cella D, DiPaola RS, Gartrell BA, et al. Quality of life (QOL) analysis from E3805, chemohormonal androgen ablation randomized trial (CHAARTED) in prostate cancer (PrCa). J Clin Oncol 34, 2016. (suppl 2S; abstr 286).
relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Morgan SC, Waldron TS, Eapen L, Mayhew LA, Winquist E, Lukka H. Adjuvant radiotherapy following radical prostatectomy for pathologic T3 or margin-positive prostate cancer: a systematic review and meta-analysis. Radiother Oncol. 2008;88(1):1–9. Epub 2008/05/27. doi: S0167-8140(08)00233-8 [pii] 10.1016/j.radonc.2008.04.013 .
Documents
Url https://pubmed.ncbi.nlm.nih.gov/18501455/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/18501455relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, et al. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol. 2015;26(8):1589–604. Epub 2015/06/05. 10.1093/annonc/mdv257
Documents
Url https://pubmed.ncbi.nlm.nih.gov/26041764/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/26041764relatesTo
type: cites
classifier: Journal Article (Citation Artifact Classifier#D016428)
citation: Kellokumpu-Lehtinen PL, Harmenberg U, Joensuu T, McDermott R, Hervonen P, Ginman C, et al. 2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. The Lancet Oncology. 2013;14(2):117–24. Epub 2013/01/09. 10.1016/s1470-2045(12)70537-5 .
Documents
Url https://pubmed.ncbi.nlm.nih.gov/23294853/ resourceReference:
https://pubmed.ncbi.nlm.nih.gov/23294853relatesTo
type: cites
citation: Kellokumpu-Lehtinen PL, Harmenberg U, Hervonen P, Joensuu TK, McDermott RS, Ginman C, et al. Triweekly docetaxel versus biweekly docetaxel as a treatment for advanced castration resistant prostate cancer: Quality of life analysis. J Clin Oncol 32, 2014. (suppl 4; abstr 23).
relatesTo
type: cites
citation: NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Prostate Cancer (Version 1.2016). http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf.
relatesTo
type: cites
citation: Liaw BC, Oh WK. Is Docetaxel Chemotherapy a New Standard of Care for Metastatic Hormone-Sensitive Prostate Cancer? The American Journal of Hematology/oncology 2015; 11(9):17–20
publicationForm
PublishedIns
Type Identifier Title PublisherLocation Periodical (Published In Type#D020492) Electronic ISSN Type/1932-6203, ISOAbbreviation/PLoS One, ISSN Linking/1932-6203, Medline Title Abbreviation/PLoS One, NLM Unique ID/101285081 PloS one United States citedMedium: Internet (Cited Medium#internet)
volume: 11
issue: 6
articleDate: 2016
publicationDateText: 2016
language: English (Tags for the Identification of Languages#en)
pageString: e0157660
publicationForm
citedMedium: Internet without issue (Cited Medium#internet-without-issue)
articleDate: 2016-06-16
webLocation
classifier: Abstract (Artifact Url Classifier#abstract)
webLocation
classifier: DOI Based (Artifact Url Classifier#doi-based)
classification
type: Publishing Model (Cited Artifact Classification Type#publishing-model)
classifier: Electronic-eCollection (Citation Artifact Classifier#Electronic-eCollection)
classification
type: Chemical (Cited Artifact Classification Type#chemical)
classifier: Androgen Antagonists (#D000726), Antineoplastic Agents (#D000970), Taxoids (#D043823), Tubulin Modulators (#D050257), Docetaxel (chemical-substances#15H5577CQD; #D000077143)
classification
type: MeSH Heading (Cited Artifact Classification Type#mesh-heading)
artifact: #
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Aged (#D000368)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Androgen Antagonists (#D000726)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: therapeutic use (#Q000627)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Antineoplastic Agents (#D000970)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: therapeutic use (#Q000627)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Antineoplastic Combined Chemotherapy Protocols (#D000971)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: therapeutic use (#Q000627)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Docetaxel (#D000077143)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Humans (#D006801)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Lymphatic Metastasis (#D008207)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Male (#D008297)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Middle Aged (#D008875)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Patient Safety (#D061214)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Prostatic Neoplasms (#D011471)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: drug therapy (#Q000188)
component
component
type: qualifier ()
classifier: mortality (#Q000401)
component
component
type: qualifier ()
classifier: pathology (#Q000473)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Randomized Controlled Trials as Topic (#D016032)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Survival Analysis (#D016019)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Taxoids (#D043823)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: therapeutic use (#Q000627)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Treatment Outcome (#D016896)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Tubulin Modulators (#D050257)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: therapeutic use (#Q000627)
component
classification
type: Publication Type (Cited Artifact Classification Type#publication-type)
classifier: Journal Article (#D016428), Meta-Analysis (#D017418), Review (#D016454), Systematic Review (#D000078182)
classification
type: Knowledge Artifact Type (Cited Artifact Classification Type#knowledge-artifact-type)
classifier: Journal Article (Citation Artifact Classifier#D016428)
artifactAssessment: : Classifier added by Computable Publishing LLC
classification
type: Citation Subset (Cited Artifact Classification Type#citation-subset)
classifier: IM (elements_descriptions.html#citationsubset#IM)
contributorship
complete: true
entry
name: Tobias Engel Ayer Botrel
forenameInitials: TE
affiliation:
- : Evidencias - A Kantar Health Company, Campinas, São Paulo, Brazil.
- : Comitê Brasileiro de Estudos em Uro-Oncologia - CoBEU, São Paulo, São Paulo, Brazil.
entry
name: Otávio Clark
forenameInitials: O
affiliation:
- : Evidencias - A Kantar Health Company, Campinas, São Paulo, Brazil.
- : Comitê Brasileiro de Estudos em Uro-Oncologia - CoBEU, São Paulo, São Paulo, Brazil.
entry
name: Antônio Carlos Lima Pompeo
forenameInitials: AC
affiliation: : Comitê Brasileiro de Estudos em Uro-Oncologia - CoBEU, São Paulo, São Paulo, Brazil.
entry
name: Francisco Flávio Horta Bretas
forenameInitials: FF
affiliation: : Comitê Brasileiro de Estudos em Uro-Oncologia - CoBEU, São Paulo, São Paulo, Brazil.
entry
name: Marcus Vinicius Sadi
forenameInitials: MV
affiliation: : Comitê Brasileiro de Estudos em Uro-Oncologia - CoBEU, São Paulo, São Paulo, Brazil.
entry
name: Ubirajara Ferreira
forenameInitials: U
affiliation: : Comitê Brasileiro de Estudos em Uro-Oncologia - CoBEU, São Paulo, São Paulo, Brazil.
entry
name: Rodolfo Borges Dos Reis
forenameInitials: R
affiliation: : Comitê Brasileiro de Estudos em Uro-Oncologia - CoBEU, São Paulo, São Paulo, Brazil.
Generated Narrative: Practitioner #author0
name: Tobias Engel Ayer Botrel
Generated Narrative: Practitioner #author1
name: Otávio Clark
Generated Narrative: Practitioner #author2
name: Antônio Carlos Lima Pompeo
Generated Narrative: Practitioner #author3
name: Francisco Flávio Horta Bretas
Generated Narrative: Practitioner #author4
name: Marcus Vinicius Sadi
Generated Narrative: Practitioner #author5
name: Ubirajara Ferreira
Generated Narrative: Practitioner #author6
name: Rodolfo Borges Dos Reis
Generated Narrative: ArtifactAssessment #meshHeading0
artifact: #
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Aged (#D000368)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Androgen Antagonists (#D000726)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: therapeutic use (#Q000627)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Antineoplastic Agents (#D000970)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: therapeutic use (#Q000627)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Antineoplastic Combined Chemotherapy Protocols (#D000971)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: therapeutic use (#Q000627)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Docetaxel (#D000077143)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Humans (#D006801)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Lymphatic Metastasis (#D008207)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Male (#D008297)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Middle Aged (#D008875)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Patient Safety (#D061214)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Prostatic Neoplasms (#D011471)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: drug therapy (#Q000188)
component
component
type: qualifier ()
classifier: mortality (#Q000401)
component
component
type: qualifier ()
classifier: pathology (#Q000473)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Randomized Controlled Trials as Topic (#D016032)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Survival Analysis (#D016019)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Taxoids (#D043823)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: therapeutic use (#Q000627)
component
content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Treatment Outcome (#D016896)
freeToShare: true
Components
Type Classifier qualifier () is not a major topic () content
informationType: classifier
type: components (if present) include qualifier codings (Cited Artifact Classification Type#mesh-heading "MeSH heading")
classifier: Tubulin Modulators (#D050257)
freeToShare: true
component
type: qualifier ()
classifier: is not a major topic ()
component
type: qualifier ()
classifier: therapeutic use (#Q000627)
component
IG © 2022+ HL7 International / Clinical Decision Support. Package hl7.fhir.uv.ebm#1.0.0-ballot based on FHIR 5.0.0. Generated 2024-04-27
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change